Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation

US6391300B1 · kind B1 · utility

Assignee

• The Trustees of Columbia University in the City of New York · US

Inventors

• Eric Rose · Dobbs Ferry, US
• David M. Stern · Great Neck, US
• Ann Marie Schmidt · Franklin Lakes, US
• Talia Spanier · New York, US

Key dates

• Filing date: Nov 16, 1998
• Grant date: May 21, 2002
• Expiry date: Nov 16, 2018

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/9645
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 &mgr;g/ml plasma to about 250 &mgr;g/ml plasma or from about 0.5 &mgr;g/ml plasma to about 25 &mgr;g/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a…